Unrealistic Expectations for Many Men With Localized Prostate CA

This article originally appeared here.
Share this content:
Unrealistic Expectations for Many Men With Localized Prostate CA
Unrealistic Expectations for Many Men With Localized Prostate CA

THURSDAY, May 19, 2016 (HealthDay News) -- Men with localized prostate cancer (LPC) often have unrealistic survival expectations, according to a study published in the May/June issue of the Annals of Family Medicine.

Jinping Xu, M.D., from Wayne State University in Detroit, and colleagues examined the survival expectations of a sample of 260 patients with LPC with and without their chosen treatment. Participants, aged 75 years or younger, completed a self-administered survey.

The researchers found that 33, 41, 21, and 5 percent of patients expected that they would live for less than five years, five to 10 years, 10 to 20 years, and more than 20 years without any treatment. With their chosen treatment, 3, 9, 33, and 55 percent, respectively, expected to live less than five years, five to 10 years, 10 to 20 years, and more than 20 years. The differences in perceived life expectancy were predicted by treatment chosen, age, general health perception, and perceived cancer seriousness, but not by race and actual tumor risk. Men who chose surgery or radiation expected greater survival gains than men who chose watchful waiting or active surveillance, after adjustment for other covariates.

"Most patients with LPC underestimated their life expectancy without treatment and overestimated the gain in life expectancy with surgery or radiation," the authors write. "These unrealistic expectations may compromise patients' ability to make informed treatment decisions and may contribute to overtreatment of LPC."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »